Table 6.
Estimate of expected number of cancers and observed number of cancers during the study period, including total standardized incidence ratio (SIR), observed versus expected (O/E)
| Group | Estimated number of cancers | Observed number of cancers | |||||
|---|---|---|---|---|---|---|---|
| Method A | Method B (PYRS) | ||||||
| Lowest estimate | Best estimate | Highest estimate | Lowest estimate | Best estimate | Highest estimate | ||
| 2 (2 FDR) | 0.1 | 0.2 | 0.3 | 0.1 | 0.2 | 0.3 | 0 |
| 3a (3 FDR) | 0.4 | 1.0 | 1.8 | 0.4 | 1.0 | 1.8 | 0 |
| 3b (Amsterdam)a | 0.7 | 1.5 | 2.7 | 0.7 | 1.6 | 3.0 | 0 |
| 3c (HCRC) | 3.6 | 7.9 | 11 | 3.1 | 6.7 | 9.2 | l |
| Total | 4.9 | 10.5 | 16 | 4.3 | 9.5 | 14.2 | l |
| Total SIR O/E (CI 95 %) | 0.20 (0.0027–1.135) | 0.10 (0.0012–0.5299) | 0.06 (0.0008–0.3477) | 0.23 (0.0030–1.294) | 0.11 (0.0014–0.5857) | 0.07 (0.0009–0.3918) | |
aGroup 3b (Amsterdam) was assessed as having a relative risk for CRC corresponding to patients in group 22 (3 FDR)